Accel Pharma is a top-tier pharmaceutical research and development firm centered on creating breakthrough therapies for underserved chronic illnesses with sparse existing treatment options. Founded in 2010, the company has rapidly grown its footprint across 25 countries, with headquarters in Boston, London, and Singapore. Its core mission is to accelerate the delivery of life-changing treatments to patients who have been excluded from effective care for their conditions.
The company’s drug development portfolio includes more than 35 active drug candidates, ranging across initial discovery phases to late-stage clinical trials across four key therapeutic areas: cancer care, immune system disorders, neurology, and rare disease therapeutics. Its flagship drug candidate targeting a rare childhood cancer has shown promising results in phase 2 trials, with treatment response metrics exceeding industry benchmarks by 28%, marking a significant step forward in treating a condition with no previously approved therapies.
Accel Pharma leverages cutting-edge technologies including artificial intelligence-powered target identification to cut drug development timeframes by up to 30% and enhance the likelihood of regulatory approval for new drug candidates. The organization also partners with prestigious medical research centers and international non-profit health groups to broaden treatment availability in resource-limited healthcare markets. These partnerships have enabled Accel Pharma to fast-track the development of affordable generics for common chronic conditions that present financial barriers to care for most patients in emerging markets.
To date, the company has been granted regulatory approval for 12 of its drug candidates in leading healthcare markets including the US, EU, and Japan. Its dedication to reducing healthcare disparities has led to cost-support initiatives that enable underinsured patients to afford care regardless of their income level or insurance status. Earlier this year, Accel Pharma launched a international patient support scheme to provide free or low-cost doses of its approved immunotherapy drugs to underserved communities across the Global South, with plans to expand the program to 18 more markets by 2025.
Alongside its primary pharmaceutical activities, Accel Pharma has implemented strict environmental sustainability policies to reduce its carbon footprint by 45% by 2030, with targets to achieve zero net greenhouse gas output by 2040. The company also adheres to strict ethical guidelines for all its clinical trials, with transparent participant consent frameworks and third-party review to protect patient safety at every stage of the research process.
In the coming years, Accel Pharma plans to broaden its therapeutic candidate roster to include Alzheimer's therapies and gene editing therapies for rare inherited conditions, with 10 new candidates entering early-stage clinical trials by the end of 2025. The organization's overarching mission is to address unaddressed patient needs for over 1 billion people living with orphan and long-term illnesses by 2035, while maintaining its commitment to affordability for all approved therapies.